Boston, USA-based company building the leading platform for cell programming and biosecurity, Ginkgo Bioworks acquired an innovative life sciences tools, diagnostics and computational discovery company, Proof Diagnostics. The company announced the acquisition on February 28, 2024. However, it did not disclose the amount of the transaction.
Purpose of the acquisition by Ginkgo Bioworks
Ginkgo Bioworks seeks to expand its offerings with the latest acquisition of Proof Diagnostics.
The current collaboration between it and Arbour Biotechnologies aims to progress the creation of precision gene editors. The acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform was announced by Ginkgo last year. Ginkgo is integrating StrideBio’s expertise into their end-to-end platform for developing AAV gene therapy. This allows Ginkgo’s clients to take advantage of these new resources in order to enhance the safety profile and more precisely target their upcoming gene therapies.
What the Ginkgo Bioworks official has to comment
Jason Kelly, CEO and co-founder of Ginkgo Bioworks, said, “Ginkgo is committed to building world-class capabilities in engineering genetic medicines. Integrating Proof’s technologies and libraries gives our customers a new tool to overcome the limitations of current gene editing systems. We don’t believe that there is a one-size-fits-all approach to biology. Biology is complex, and that complexity demands a wide array of tools and approaches – we are proud to be building that toolbox at Ginkgo.”
What the Proof Diagnostics official has to add
Sid Shenai, CEO and co-founder of Proof Diagnostics, further said, “We are excited for Ginkgo to integrate Proof’s OMEGA nuclease and related technologies into its genetic medicines programs. These enzymes are more compact and diverse than other classes of programmable nucleases – including CRISPR Cas – and are a powerful addition to the gene editing toolkit for therapeutics. The entire Proof team has admired Ginkgo’s progress for many years and is confident that the team at Ginkgo is uniquely well-suited to advance the full scope of Proof’s technologies to serve customers and patients worldwide.”
About Proof Diagnostics
Dr. Feng Zhang, Omar Abudayyeh and Sid Shenai are the co-founders of Proof Diagnostics. In addition to discovering genome engineering tools for therapeutic and diagnostic applications, Proof Diagnostics—a cutting-edge life sciences tools, diagnostics, and computational discovery company—developed a clever, portable system for the detection of infectious and other disorders.
To leverage CRISPR-based and other technologies to produce a low-cost, quick, simple, and sensitive diagnostic method for SARS-CoV-2, Flu A/B, RSV, and other disorders, including oncology. The main objective of Ginkgo’s acquisition is Proof’s libraries of OMEGA (Obligate Mobile Element Guided Activity) RNA programmable, non-Cas enzymes and related intellectual property.
To explore more such startups, visit Zefyron Startup Database
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
